News

Boston Scientific (BSX) reported Q2 revenue and EPS that beat expectations but lowered its full-year

BSX faces WATCHMAN and EP pressures as management cuts outlook while highlighting cost savings and new product catalysts for future growth.

Moby summary of Boston Scientific Corporation's Q2 2026 earnings call

Boston Scientific (NYSE:BSX) reported second-quarter 2026 revenue growth at the high end of its guidance range and adjusted earnings per share above expectations, but lowered its full-year outlook as it faces slowing demand in its WATCHMAN left atrial appendage closure business and increased competi

Boston Scientific Corp (BSX) reports a robust Q2 with 7% organic sales growth and a 15% increase in adjusted EPS, despite challenges in some segments.

Although the revenue and EPS for Boston Scientific (BSX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

The medical device maker topped second-quarter expectations but now sees full-year adjusted EPS of $3.28 to $3.32, down from a prior range of $3.34 to $3.41

BSX beats Q2 earnings and revenue estimates as cardiovascular growth, strong APAC and LACA sales, and margin expansion lift shares in pre-market.

Boston Scientific (BSX) delivered earnings and revenue surprises of +3.61% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Medical device company Boston Scientific (NYSE:BSX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.5% year on year to $5.44 billion. On the other hand, next quarter’s revenue guidance of $5.27 billion was less impressive, coming in 2.2% below analysts’ estimates. Its non-GAAP profit of $0.86 per share was 3.8% above analysts’ consensus estimates.

Medical device company Boston Scientific (NYSE:BSX) will be reporting earnings this Wednesday morning. Here’s what to expect.

Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.

BSX faces Q2 results with growth expected in key businesses, but lowered full-year guidance, cost pressures and weak stock performance cloud the outlook.

Shareholders of Boston Scientific would probably like to forget the past six months even happened. The stock dropped 52.5% and now trades at $42.79. This was partly driven by its softer quarterly results and might have investors contemplating their next move.

Boston Scientific is gearing up for earnings day, weighing a rocky stock run against Wall Street's stubbornly optimistic outlook.

In late April 2026, Boston Scientific reported quarterly revenue of US$5.20 billion, up 11.6% year on year and ahead of expectations, but cut near-term and full-year guidance amid intensifying cardiac market competition and slowing growth in its Watchman stroke-prevention device. This combination of strong recent performance and a more cautious outlook, reinforced by downgrades from firms like Wolfe Research, has sharpened investor focus on how resilient Boston Scientific’s growth drivers...

Boston Scientific (BSX) shares fell Wednesday after Chief Executive Mike Mahoney's comments about fl

Investors weigh softer WATCHMAN and urology demand against a still-active device pipeline and capital deployment moves, today, May 27, 2026.

Boston Scientific's CEO stated that the company will update its three-year plan, including targets for FY27 and FY28, after the third-quarter earnings call.

The Dow Jones Industrial Average was up, while the S&P 500 and Nasdaq Composite were about flat in l

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Moby summary of Elutia Inc.'s Q1 2026 earnings call

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...